ERBB2 and cancer: In recent times, long-term HER2-blockade has proven crucial in enhancing survival in HER2 enriched cancers [26], transforming the natural history of this disease into one of chronicity, with clinical outcomes comparable to even the most favourable of luminal cancers [27].